Medtronic announced FDA clearance and CE Mark for its latest Affera Prism-2 Mapping Software and CE Mark for the PulseSelect ProxBox Adapter with Proximity Indicator software. These upgrades enhance cardiac ablation procedures by providing detailed 3D heart maps and real-time tissue proximity feedback, helping physicians improve precision and reduce reliance on X-ray imaging. The innovations support better treatment for heart rhythm disorders and expand Medtronic's cardiac ablation technology portfolio globally.
Medtronic PLC shares are trading at USD 87.26 on Pluang as of Sep 30, 2026 20:15 WIB, showing a modest 0.20% increase in the past day. The company holds a substantial market capitalization of $111.40 billion, reflecting its significant presence in the health sector. Investor interest appears strong with 100% buy orders recorded on Pluang, indicating confidence in Medtronic's ongoing innovations.
